Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.58 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425315 | 0.96 | BRD4 (0.63) | BRD4ATAD2AVPR2AVPR1ACA12 | |
| SCHEMBL2081974 | 0.90 | CA12 (0.56) | BRD4ATAD2CA12CA1CA2 | |
| SCHEMBL12476172 | 0.84 | CA1 (0.56) | BRD4ATAD2AVPR2AVPR1ACA12 | |
| SCHEMBL396278 | 0.81 | BRD4 (0.62) | BRD4ATAD2AVPR2AVPR1APDK1 | |
| SCHEMBL2616894 | 0.79 | MAPT (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2616853 | 0.79 | CA12 (0.44) | BRD4ATAD2AVPR2AVPR1ACA12 | |
| SCHEMBL13041657 | 0.79 | ALDH1A1 (0.51) | BRD4ATAD2CA12CA1CA2 | |
| SCHEMBL2616854 | 0.78 | RAB9A (0.45) | BRD4ATAD2CA12CA1CA2 | |
| SCHEMBL2081068 | 0.78 | CA12 (0.67) | BRD4ATAD2AVPR2CA12CA1 | |
| SCHEMBL396271 | 0.78 | BRD4 (0.69) | BRD4ATAD2AVPR2AVPR1APDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | BRD4 1294/4885ATAD2 3991/4885AVPR2 4551/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | BRD4 557/4885ATAD2 4143/4885AVPR2 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.